Gilead Sciences Stock Surges 3.16% in Two Days, Trading Volume Ranks 131st

Gilead Sciences (GILD) shares rose 1.81% on June 6, 2025, marking the second consecutive day of gains, with a total increase of 3.16% over the past two days. The trading volume was $590 million, down 50.79% from the previous day, ranking 131st in the day's trading volume.

Gilead Sciences is awaiting FDA approval for its long-acting HIV drug, lenacapavir. The FDA accepted the company's New Drug Application (NDA) for lenacapavir in February, with a target action date set for June 19, 2025. The drug, administered twice a year, has shown 100% efficacy in preventing HIV in cisgender women, based on interim results from the Phase 3 PURPOSE 1 trial. This led to the trial's blinded phase being stopped early, with all participants offered open-label lenacapavir.

Gilead's HIV treatment portfolio and pipeline were highlighted at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in March. The company's stock has gained almost 74% since June 2024 and has jumped around 21% year-to-date. Despite this momentum, Gilead's stock is trading at 13.3 times forward earnings, below the pharmaceutical industry average of 14.

Investors may be cautious due to Gilead's past experiences with hepatitis C treatments, where stock surges were followed by declines as demand faded. However, Gilead's HIV drug Biktarvy is protected from generic competition until 2033, and the company has several next-generation HIV treatments in development. In the first quarter of 2025, HIV product sales increased 6% year-over-year to $4.59 billion.

Gilead aims to more than double U.S. PrEP users to over one million in the next 10 years, with analysts expecting $4 billion in annual sales by 2030. The company is well-positioned compared to other drugmakers facing upcoming patent expirations. However, there are concerns about potential reductions in federal funding for domestic HIV prevention, which could impact Gilead's market growth.